In glucocorticoid-remediable aldosteronism (GRA), there is a large interfamily variation of phenotype. We report three subjects with GRA in a single family (parents, two brothers and two sisters), of whom only one (proband) displayed classical features of the mineralocorticoid excess. The proband was a man found to be hypertensive and hypokalaemic at the age of 24 years. Plasma renin activity was suppressed and plasma aldosterone was repeatedly elevated. Blood pressure and aldosterone levels normalized within 5 days of dexamethasone therapy. The presence of a chimaeric CYP11B1/CYP11B2 gene was demonstrated by long-PCR and Southern blotting (crossover site at the end of intron 3) in the proband, in the younger sister (sibling 1) and in the father. In these patients, sequencing of the chimaeric portion of CYP11B1 did not reveal any mutation, while sequencing of the chimaeric portion of CYP11B2 showed a V386A polymorphism in exon 7, known to cause only a minimal impairment of enzymatic activity. Sibling 1 was normotensive, normokalaemic and had normal PRA and aldosterone. The father had normal blood pressure and potassium, low-normal PRA and normal aldosterone. All three subjects had elevated levels of urinary 18-hydroxycortisol and 18-oxocortisol. Baseline 11-deoxycorticosterone (DOC), corticosterone (B) and aldosterone were high in the proband and normal in the father and sibling 1; 11-deoxycortisol (S) and cortisol (F) were normal. ACTH induced a normal increase of B, DOC, S and F, and an excessive aldosterone increase in all three patients. Abnormalities in the chimaeric portions of CYB11B1 or CYP11B2 genes did not account for the phenotypic disparity of the different members in a single GRA family. Altered regulation of the chimaeric gene may be responsible for differences in its activity.
Introduction
Glucocorticoid-remediable aldosteronism (GRA) is a rare autosomal dominant disorder of adrenocortical steroid synthesis, in which aldosterone secretion is solely regulated by adrenocorticotropin (ACTH) rather than angiotensin II. 1 In the classical form, this syndrome is characterized by hypokalaemia, hyperaldosteronism and suppressed plasma renin activity (PRA), presents at a young age in association with familial occurrence of hypertension and cerebral haemorrhage, and is correctable by glucocorticoid therapy. 2, 3 The genetic abnormality results from the inheritance of a hybrid gene derived from the crossover between the 5 0 -regulatory ACTH-responsive sequence of the CYP11B1 (11b-hydroxylase) gene and the 3 0 -coding region of the CYP11B2 (aldosterone synthase) gene, 4 and can be detected by a reliable and simple long-PCR test. 5 A considerable interfamily variation has been described for many GRA phenotypic traits, including blood pressure, aldosterone and PRA levels, hypokalaemia and occurrence of cerebrovascular accidents, 2, 3 and no relationship between genotype and phenotype has been found. 6, 7 Scarce data are available on the intrafamily variation of phenotype in patients with genetically proved GRA. While in the family previously reported by us 8 and in that described by Rich et al, 9 the penetrance of hypertension and aldosteronism was high in all affected pedigree members, in the family of Gates et al 10 and in another one more recently reported by us, 11 the great majority of affected members had mild hypertension and normal biochemistry, including serum potassium. Here we report a new family of six members in which three subjects have been identified as possessing the same type of CYP11B1/CYP11B2 chimaeric fusion, but display diverse biochemical and clinical phenotypes.
Case reports

The Proband
A 34-year-old man was referred to our centre for evaluation of refractory hypertension. He had been initially diagnosed with hypertension and hypokalaemia at 24 years of age. Primary aldosteronism was suspected on the basis of low PRA and elevated plasma and urinary aldosterone after repeated measurements. Abdominal CT scan and 75 Semethyl-nor-cholesterol adrenal scintiscan were interpreted as showing adrenal bilateral hyperplasia, and adrenal venous catheterization revealed symmetric, elevated secretion of aldosterone. The patient had poorly controlled blood pressure for many years while on multiple medical regimen, including spironolactone, calcium-channel blockers and ACE inhibitors. He was evaluated as an outpatient on an unrestricted sodium and potassium diet, and 3 weeks after withdrawal of antihypertensive medications. There was no family history of hypertension or of early death from cerebrovascular events. The proband's blood pressure was 210/ 110 mmHg, his serum potassium was 2.5 mmol/l, upright PRA was suppressed and plasma and urinary aldosterone levels were elevated (Table 1) . Routine biochemistry and renal scintigraphy were normal. The EKG showed left ventricular hypertrophy. Urinary levels of 18-hydroxycortisol (18-OHF) and 18-oxocortisol (18-oxoF) were elevated. On a different day, ACTH 1-24 250 mg (Synacthen, Novartis Pharma) was injected as an i.v. bolus at 10.00 h into the subject after a 30-min rest in a seated position. Baseline 11-deoxycorticosterone (DOC), corticosterone (B) and aldosterone were high, and 11-deoxycortisol (S) and cortisol (F) were normal. ACTH administration induced a normal increase of B, DOC, S and F, and an excessive increase of aldosterone. After 4 days of dexamethasone treatment (0.5 mg every 6 h) blood pressure decreased, aldosterone fell to undetectable levels and serum potassium increased slightly. On a long-term basis, dexamethasone 0.250 mg/day in combination with nifedipine 10 mg t.i.d. controlled blood pressure and serum potassium levels. The presence of the chimaeric CYP11B1/CYP11B2 gene was demonstrated by long PCR and Southern blotting of genomic DNA. Sequencing of the chimaeric PCR product demonstrated that the crossover site was located at the end of intron 3, just before the beginning of exon 4.
Family screening
All living first-degree family members were analysed. The clinical, biochemical and genetic data are reported in Table 1 . Body mass index (BMI) and waist circumference were in the normal range for all members, except the affected father and the unaffected mother, who both showed mild overweight. Blood pressure measurements and baseline data were obtained in the two parents and the three siblings (one brother and two sisters), evaluated as outpatients on an unrestricted sodium and potassium diet. All siblings and the two parents were found to be normotensive and normokalaemic, and had normal plasma and urinary aldosterone. The father had low-normal PRA. No clinical conditions that could lower blood pressure, that is heart failure, were present in the father. The father and the younger sister (ie, sibling 1) had high urinary 18-OHF and 18-oxoF. In these two subjects, an ACTHstimulation test was performed, following the same protocol described above. While baseline and ACTH-stimulated plasma DOC, B, S and F were normal, aldosterone was hyper-responsive to ACTH, as in the proband (Table 2) . Sibling 1 and the father showed the same gene abnormality and the same chimaeric gene crossover point of the proband. The crossover site was in the same region found in another Italian family from Sardinia, previously described by us. 11 We analysed the sequences of the two hybrid genes to address the question of whether the gene was the same, that is, the two families had a common ancestor. In detail, we compared two polymorphisms in intron 3, one in exon 3 and one in intron 4. Both hybrid genes carried a GAA at codon 173 codifying for lysine; however, the Sardinian family displayed a G in position +12 and a T in position +119 from the end of exon 3, and a C in position +140 from the end of exon 4. The family described here had three different nucleotides at the corresponding positions (+12A/+119G/+140T), allowing us to exclude the possibility of a common ancestor. Moreover, the two Italian families were unrelated and lived in geographical areas far from each other.
Since aldosterone levels were normal in sibling 1 and the father, we evaluated the possibility of a sequence alteration in the chimaeric portion of CYP11B2 that would potentially lower aldosterone synthase activity, thus explaining the occurrence of normal aldosterone levels. Moreover, since these GRA patients and the proband had no impairment of 11b-hydroxylase, in contrast to previous findings in GRA, 18 the sequence of the chimaeric portion of CYP11B1 was also examined.
Laboratory evaluation
Plasma and urinary aldosterone, PRA and F were measured as described previously. 5 Plasma DOC, B and S were measured by an HPLC-RIA method as previously described.
12 Urinary 18-OHF and 18-oxoF were measured using an ELISA method.
13,14
Molecular analysis
Long-PCR for the amplification of the chimaeric gene and Southern blotting of genomic DNA were performed as described previously. 5, 15 In order to sequence the entire chimaeric gene, a second long-PCR was performed under similar conditions as described previously, 15 but using primers complementary to intron 3 of CYP11B1 and to 3 0 UTR of CYP11B2. The PCR products (3 kb) were purified and sequenced as described previously. 16 Primer sequences are available on request.
Discussion
In our pedigree, we report a wide variation of phenotype between individuals affected by GRA. The proband had all classical features of primary aldosteronism, that is, hypokalaemia, high aldosterone levels, suppressed PRA, in addition to the presentation of hypertension at a young age. The suppressibility of aldosterone by dexamethasone and the elevated levels of urinary 18-OHF and 18-oxoF were also consistent with the clinical diagnosis, which was confirmed genetically by the demonstration of the chimaeric CYP11B1/CYP11B2 gene. Steroid precursors of aldosterone were elevated in the proband, and DOC/B and S/F ratios were not different from normal either in baseline conditions (8 vs 10 and 0.2 vs 0.5, respectively, when expressed on an equimolar basis Â 100) or after ACTH stimulation (3 vs 2 and 0.2 vs 0.4, respectively). The B/aldosterone ratio was also not different from normal in baseline conditions (15 vs 13, expressed on an equimolar basis), but was greatly lower than normal after ACTH (30 vs 84), reflecting the hyper-responsiveness of aldosterone to ACTH stimulation typical of this disease. 8, 17 Moreover, a similar marked ACTH-induced decrease of B/aldosterone ratio due to aldosterone hyperresponse also occurred in the younger sister and in the father with GRA (45 and 20 vs 84, respectively). This steroid hormone pattern is in disagreement with findings in other studies of a deficient 11b- Different phenotypes in GRAhydroxylation in GRA, 18 but is in accordance with an increased aldosterone synthase activity in this condition. 19 The younger sister and the father were normotensive and normokalaemic. The father had PRA in the lower limit of the normal range, consistent with the age. Lack of hypertension as well as of hypokalaemia was not surprising, because this phenomenon has been frequently described. 2 Differences in major common modifiers of blood pressure levels, for example, gender, age and BMI (Table 1) , did not appear to have an important role in inducing different phenotypes within the family. In fact, the affected father, in spite of older age and mild overweight, had normotension. All family members lived in the same house, therefore suggesting that other factors potentially affecting phenotype, such as dietary patterns and lifestyle, are unlikely.
All three subjects showed the same chimaeric gene crossover point. The possibility of an additional sequence alteration in the chimaeric portion of CYP11B2, potentially lowering aldosterone synthase activity and explaining the normal aldosterone levels in two of our GRA subjects, was excluded by our study. In particular, there was no mutation or gene conversion involving sequences of exons 5 and 6 responsible for 18-hydroxylase and 18-oxidase activities. 15, 20 Moreover, in all three GRA subjects we detected the same V386A polymorphism in the chimaeric portion of CYP11B2. This polymorphism is known to cause only minimal impairment of aldosterone synthase activity in vitro, 21 and has not been seen as an isolated homozygous change in patients with corticosterone methyloxidase type I or II deficiency. 22 It is rather possible that an altered regulation of the chimaeric gene by specific inhibitors or repressors, or by other genes lying outside the locus of the chimaeric gene may be responsible for its differential expression and activity. Further, we cannot exclude the possibility that other genetic factors could interact with the penetrance of the genetic alteration associated with GRA.
